PT2906235T - Utilização de p3 de proteínas de fusão de bacteriófago como agentes ligantes amilóides - Google Patents
Utilização de p3 de proteínas de fusão de bacteriófago como agentes ligantes amilóidesInfo
- Publication number
- PT2906235T PT2906235T PT137766747T PT13776674T PT2906235T PT 2906235 T PT2906235 T PT 2906235T PT 137766747 T PT137766747 T PT 137766747T PT 13776674 T PT13776674 T PT 13776674T PT 2906235 T PT2906235 T PT 2906235T
- Authority
- PT
- Portugal
- Prior art keywords
- fusion proteins
- binding agents
- amyloid binding
- bacteriophage
- bacteriophage fusion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261708709P | 2012-10-02 | 2012-10-02 | |
| US201261730316P | 2012-11-27 | 2012-11-27 | |
| US201361801349P | 2013-03-15 | 2013-03-15 | |
| US201361828105P | 2013-05-28 | 2013-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2906235T true PT2906235T (pt) | 2017-09-28 |
Family
ID=49354958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT137766747T PT2906235T (pt) | 2012-10-02 | 2013-10-01 | Utilização de p3 de proteínas de fusão de bacteriófago como agentes ligantes amilóides |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9688728B2 (pt) |
| EP (1) | EP2906235B1 (pt) |
| JP (1) | JP6283366B2 (pt) |
| KR (1) | KR102101258B1 (pt) |
| CN (1) | CN104870008B (pt) |
| AR (1) | AR092879A1 (pt) |
| AU (1) | AU2013327472B2 (pt) |
| BR (1) | BR112015007424A2 (pt) |
| CY (1) | CY1120132T1 (pt) |
| DK (1) | DK2906235T3 (pt) |
| EA (1) | EA033666B1 (pt) |
| ES (1) | ES2641373T3 (pt) |
| HK (1) | HK1213775A1 (pt) |
| HR (1) | HRP20171413T1 (pt) |
| HU (1) | HUE036893T2 (pt) |
| IL (1) | IL238021B (pt) |
| LT (1) | LT2906235T (pt) |
| MX (1) | MX358755B (pt) |
| NZ (1) | NZ706838A (pt) |
| PL (1) | PL2906235T3 (pt) |
| PT (1) | PT2906235T (pt) |
| SI (1) | SI2906235T1 (pt) |
| TW (1) | TWI613212B (pt) |
| WO (1) | WO2014055515A1 (pt) |
| ZA (1) | ZA201502940B (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA029602B1 (ru) | 2011-11-29 | 2018-04-30 | Проклара Байосайенсиз, Инк. | Применение белков р3 бактериофага в качестве агентов, связывающих амилоид |
| EA033666B1 (ru) | 2012-10-02 | 2019-11-14 | Proclara Biosciences Inc | Амилоидсвязывающие белки и их применение |
| AU2014274253B2 (en) * | 2013-05-28 | 2018-06-14 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
| KR20170085132A (ko) | 2014-12-03 | 2017-07-21 | 프로클라라 바이오사이언시즈, 인크. | 글리코실화 신호가 결핍된 변형된 박테리오파지 ｇ3ｐ 아미노산 서열을 포함하는 폴리펩티드 |
| TWI735433B (zh) * | 2015-03-27 | 2021-08-11 | 美商再生元醫藥公司 | 偵測生物污染物之組成物及方法 |
| EP3532497A4 (en) | 2016-10-26 | 2020-05-13 | The Board of Trustees of the Leland Stanford Junior University | MODIFIED IMMUNOGLOBULIN BAND REGIONS TO REDUCE HEMAGGLUTINATION |
| PL3806884T3 (pl) | 2018-06-15 | 2023-11-20 | Amyl Therapeutics | Ogólny motyw oddziaływania z amyloidem (gaim) |
| CN115605483A (zh) | 2020-07-06 | 2023-01-13 | 莫尔根生物有限公司（Kr） | 三环双内酯化合物、其生产方法及用途 |
| WO2023230282A1 (en) * | 2022-05-25 | 2023-11-30 | The General Hospital Corporation | Modulation of bace1 as a therapy for spinocerebellar ataxia |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| EP0939121B2 (de) | 1989-09-12 | 2007-12-26 | AHP Manufacturing B.V. | TFN-bindende Proteine |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| SG47099A1 (en) | 1991-03-15 | 1998-03-20 | Amgen Boulder Inc | Pegylation of polypeptides |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| ATE311895T1 (de) | 1992-05-26 | 2005-12-15 | Immunex Corp | Neue zytokine die cd30 binden |
| CA2290485C (en) | 1997-05-21 | 2008-08-05 | Biovation Limited | Method for the production of non-immunogenic proteins |
| CN1202128C (zh) | 1998-12-08 | 2005-05-18 | 拜奥威神有限公司 | 修饰蛋白的免疫原性 |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| US6376117B1 (en) | 2000-07-18 | 2002-04-23 | Sofco L.P. | Internal fuel staging for improved fuel cell performance |
| US8022270B2 (en) | 2000-07-31 | 2011-09-20 | Biolex Therapeutics, Inc. | Expression of biologically active polypeptides in duckweed |
| EP1361891A2 (en) | 2001-02-19 | 2003-11-19 | MERCK PATENT GmbH | Artificial fusion proteins with reduced immunogenicity |
| ATE339446T1 (de) | 2001-03-08 | 2006-10-15 | Merck Patent Gmbh | Modifizierter humaner granulozyten makrophagen kolonien stimulierender faktor (gm-csf) mit reduzierter immunogenität |
| WO2003031611A2 (en) * | 2001-10-05 | 2003-04-17 | Cangene Corporation | Phagemid display system |
| DE10238846A1 (de) | 2002-08-20 | 2004-03-04 | Nemod Immuntherapie Ag | Aktive Fusionsproteine und Verfahren zu ihrer Herstellung |
| PT1853285E (pt) | 2005-02-01 | 2011-06-06 | Univ Ramot | Método para tratamento de inflamação associada a depósitos de amilóide e inflamação cerebral envolvendo microglia activada |
| CA2642473A1 (en) | 2006-02-15 | 2007-08-23 | Ramot At Tel Aviv University | Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain |
| WO2007094003A2 (en) | 2006-02-15 | 2007-08-23 | Ramot At Tel Aviv University Ltd. | Viral display vehicles for treating multiple sclerosis |
| WO2007109733A2 (en) | 2006-03-21 | 2007-09-27 | The Johns Hopkins University | Diagnostic and prognostic markers and treatment strategies for multiple sclerosis |
| WO2007114139A1 (ja) * | 2006-04-06 | 2007-10-11 | Fumiaki Uchiyama | 新規繊維状ファージによるファージディスプレイ |
| JP2009544718A (ja) * | 2006-07-21 | 2009-12-17 | ラモット・アット・テルアビブ・ユニバーシティ | タンパク質の繊維性封入体または凝集体の細胞内形成に関連する疾患を処置するための接着タンパク質からのペプチドをディスプレイするファージの使用 |
| CA2666320A1 (en) | 2006-10-11 | 2008-04-17 | Antitope Limited | T cell epitope databases |
| EP2303315A1 (en) | 2008-05-22 | 2011-04-06 | Ramot at Tel Aviv University Ltd. | Method for treating disease characterized by plaque |
| RU2011125971A (ru) | 2008-11-24 | 2012-12-27 | Рамот Эт Тель-Авив Юниверсити Лтд. | Способ лечения болезни паркинсона |
| EP2233500A1 (en) * | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| WO2011084714A2 (en) | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| JP2014509514A (ja) | 2011-03-11 | 2014-04-21 | ラモット アット テルアヴィブ ユニヴァーシティ リミテッド | 神経変性タウオパシーを治療するための方法 |
| EA029602B1 (ru) | 2011-11-29 | 2018-04-30 | Проклара Байосайенсиз, Инк. | Применение белков р3 бактериофага в качестве агентов, связывающих амилоид |
| EA033666B1 (ru) | 2012-10-02 | 2019-11-14 | Proclara Biosciences Inc | Амилоидсвязывающие белки и их применение |
| AU2014274253B2 (en) | 2013-05-28 | 2018-06-14 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
| KR20170085132A (ko) | 2014-12-03 | 2017-07-21 | 프로클라라 바이오사이언시즈, 인크. | 글리코실화 신호가 결핍된 변형된 박테리오파지 ｇ3ｐ 아미노산 서열을 포함하는 폴리펩티드 |
-
2013
- 2013-10-01 EA EA201590690A patent/EA033666B1/ru unknown
- 2013-10-01 WO PCT/US2013/062862 patent/WO2014055515A1/en active Application Filing
- 2013-10-01 PL PL13776674T patent/PL2906235T3/pl unknown
- 2013-10-01 AU AU2013327472A patent/AU2013327472B2/en active Active
- 2013-10-01 SI SI201330758T patent/SI2906235T1/sl unknown
- 2013-10-01 JP JP2015534813A patent/JP6283366B2/ja active Active
- 2013-10-01 DK DK13776674.7T patent/DK2906235T3/en active
- 2013-10-01 NZ NZ706838A patent/NZ706838A/en not_active IP Right Cessation
- 2013-10-01 MX MX2015004119A patent/MX358755B/es active IP Right Grant
- 2013-10-01 TW TW102135558A patent/TWI613212B/zh not_active IP Right Cessation
- 2013-10-01 HU HUE13776674A patent/HUE036893T2/hu unknown
- 2013-10-01 US US14/432,861 patent/US9688728B2/en active Active
- 2013-10-01 LT LTEP13776674.7T patent/LT2906235T/lt unknown
- 2013-10-01 CN CN201380061794.6A patent/CN104870008B/zh not_active Expired - Fee Related
- 2013-10-01 ES ES13776674.7T patent/ES2641373T3/es active Active
- 2013-10-01 KR KR1020157011456A patent/KR102101258B1/ko active IP Right Grant
- 2013-10-01 PT PT137766747T patent/PT2906235T/pt unknown
- 2013-10-01 BR BR112015007424-3A patent/BR112015007424A2/pt not_active Application Discontinuation
- 2013-10-01 EP EP13776674.7A patent/EP2906235B1/en active Active
- 2013-10-02 AR ARP130103572A patent/AR092879A1/es unknown
-
2015
- 2015-03-30 IL IL238021A patent/IL238021B/en active IP Right Grant
- 2015-04-29 ZA ZA2015/02940A patent/ZA201502940B/en unknown
-
2016
- 2016-02-18 HK HK16101718.1A patent/HK1213775A1/zh unknown
-
2017
- 2017-05-04 US US15/587,180 patent/US10208090B2/en active Active
- 2017-09-19 HR HRP20171413TT patent/HRP20171413T1/hr unknown
- 2017-09-20 CY CY20171100988T patent/CY1120132T1/el unknown
-
2018
- 2018-05-09 US US15/975,328 patent/US10526377B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1213775A1 (zh) | 噬菌體的 融合蛋白作爲澱粉樣蛋白結合劑的用途 | |
| HK1216538A1 (zh) | 人類微管相關蛋白抗體 | |
| HK1192587A1 (zh) | 治療性融合蛋白 | |
| EP2877854A4 (en) | FUSION PROTEINS AND METHOD THEREFOR | |
| EP2929045A4 (en) | PROTEIN EXPRESSION REINFORCING POLYPEPTIDES | |
| HK1213521A1 (zh) | 多肽的應用 | |
| EP2782589A4 (en) | ANTIMICROBIAL PEPTIDES AND METHOD FOR THEIR USE | |
| HK1216159A1 (zh) | 治療性融合蛋白 | |
| SG11201402425TA (en) | Use of p3 of bacteriophage as amyloid binding agents | |
| EP2711376A4 (en) | FGFR-FC FUSION PROTEIN AND USE THEREOF | |
| EP2683742A4 (en) | NPP1 FUSION PROTEIN | |
| EP2825549A4 (en) | SYNTHETIC PROTEINS STABILIZED FROM THE CONFORMATIONAL VIEWPOINT | |
| EP2930189A4 (en) | CHEMOKINE-CYTOKINE FUSION PROTEIN AND USE THEREOF | |
| EP2922871A4 (en) | METHODS AND COMPOSITIONS FOR FACTOR IX PROTEINS | |
| HK1204948A1 (en) | Radiation-sterilization-resistant protein composition | |
| EP3560952C0 (en) | VARIANT OF BPIFB4 PROTEIN | |
| ME02851B (me) | Upotreba p3 bakteriofagni fuzionih proteina kao vezujućih agenasa amiloida | |
| GB201213672D0 (en) | Protein | |
| GB201200743D0 (en) | Protein bridges | |
| GB201215901D0 (en) | Protein modification | |
| EP2817324A4 (en) | NEMO BOND DOMAIN FUSION PROTEINS | |
| GB201114701D0 (en) | Fusion proteins | |
| GB201107189D0 (en) | Fusion proteins |